Amphastar (AMPH) Q3 2026 Earnings Call Transcript

Amphastar reported record Q3 2026 revenue of $207.6 million, up 8% year over year, and adjusted diluted EPS of $1.14 versus $0.93 a year earlier. Growth in BAQSIMI and Primatene MIST was partly offset by gross margin compression to 48.0% from 51.4%, lower sales of some IMS products, and $2 million to $3 million of additional IMS remediation expenses; management expects those expenses to be higher in each of the next two to three quarters. The company expects high-single-digit Q4 revenue growth and its board authorized an additional $50 million for share repurchases, while the insulin aspart launch remains targeted for 2027 subject to FDA approval. The results and outlook are balanced by continuing manufacturing constraints and pricing pressure.

Analysis

The key issue is conversion, not demand: IMS constraints leave revenue in backlog while remediation adds cost and absorbs capacity. If controls ease, shipments could provide a near-term revenue tailwind; however, backlog is not equivalent to recognized sales, and clearing it may compete with shortage-driven lidocaine demand and other products for constrained resources. Treat management’s capacity timeline as unverified until releases and costs improve together.

The quarter’s earnings signal is less clean than the top line: lower pricing on BAQSIMI, glucagon and epinephrine pressures margins, while the prior-year legal settlement distorts the reported G&A comparison. BAQSIMI volume growth is constructive, but management’s admission that net pricing will not return to historical levels makes this a durable offset to volume, not simply a temporary 340B cleanup. Primatene’s price-led growth also merits monitoring for unit elasticity. Lidocaine’s shortage benefit is vulnerable to competitor supply recovery; glucagon competition is a more direct structural risk.

Over 1–3 months, watch IMS expense, backlog conversion and Q4 delivery against guidance. Over 6–18 months, insulin aspart could improve capacity utilization, but approval, launch timing and competitive economics remain open; do not capitalize it as a near-term margin catalyst. The contrarian read is that record revenue and adjusted EPS may invite a quality-growth multiple, while mix, remediation and pricing put persistence in doubt. Conversely, successful remediation could release upside not captured by current constrained shipments. The thesis is falsified positively by sustained margin recovery alongside falling backlog, and negatively by renewed release delays or further gross-margin deterioration.

Key Decisions for Investors

• Do not chase AMPH solely on record sales or EPS. Keep exposure measured until a quarter shows both lower IMS remediation costs and better gross margin; a backlog decline without improving shipments or margins is not confirmation.
• Set a 1–3 month alert for IMS releases, backlog and remediation expense. Reassess positively if backlog converts while costs fall; reduce or avoid exposure if FDA-related controls cause further delays or the backlog grows.
• Model BAQSIMI with persistent net-price pressure rather than a return to historical pricing. Track unit growth against net sales and rebate/340B commentary; weakening sales despite volume growth would challenge the franchise thesis.
• Treat lidocaine shortage-driven sales and the 2027 insulin aspart launch as conditional upside, not base-case earnings. Verify competitor supply normalization and insulin FDA approval/timing before underwriting durable growth.